Record mula sa primary source
Natanggap ng Tvardi ang nakasulat na mga tugon ng FDA sa pakete nito para sa pre-IND na pagpupulong para sa TTI-109 sa ulcerative colitis (na may Crohn’s disease bilang potensyal na karagdagang indikasyon). Sumang-ayon ang FDA na ang mga nakabalangkas na nonclinical na pag-aaral ay sumusuporta sa isang Phase 2 na pagsubok at nagbigay ng gabay sa dosing, disenyo ng pag-aaral at pagpili ng pasyente. Plano ng kumpanya na isumite ang IND sa 2027.
EX-99.1 2 tm2630209d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback New analysis of Phase 1 exposure data supports the potential for sustained STAT3 inhibition at proposed clinical doses, with minimal predicted effect on STAT1 and STAT5 HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it has received written responses from the U.S. Food and Drug Administration (FDA) to its pre-Investigational Ne